ERT Acquires eClinical Insights
ERT announced the acquisition of eClinical Insights
ERT, a global solution provider for high-quality patient safety and efficacy endpoint data collection, announced the acquisition of eClinical Insights, a provider of cloud-based clinical trials management software.
eClinical Insights' technology platform includes a suite of products--InTrial Metrix, TrialOps Director, Dataflow Manager, EndPoint Reviewer--that work across disparate systems and diverse global clinical trials teams. On average, clinical trial sponsors utilize between 5-7 systems for data collection from disparate vendors. ERT’s EXPERT platform combined with eClinical Insights' product suite,will enable clients to benefit from a data integration layer that enables real-time data exchange between systems. The end result is comprehensive insight into investigative site and outcomes data activity across all spectrums.
eClinical Insights had changed its name from PharmaPros almost one year ago.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
